The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam’s Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 117 stocks made new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's morning session saw 27 companies set new 52-week lows.
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 20)
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 64 stocks made new 52-week lows.
The Daily Biotech Pulse: Lilly, Morphic’s Positive Data At ECCO, Humanigen’s COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Ensysce Biosciences Receives Notice of Award For 3 Of Multi-Year National Institute On Drug Abuse Grant For Clinical Development Of Next Generation Opioid Products With Overdose Protection; Grant Will Provide $2.8M For Phase 1 Study
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "the Company"), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of
Ensysce Biosciences To Begin Trading On Nasdaq On July 2
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW) today announced that the Company will begin trading its common stock under the ticker symbol "ENSC" on The